Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 13/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8286263 | 0.93 | CSF1R (0.44) | CSF1RLMNA | |
| SCHEMBL12226825 | 0.87 | CSF1R (0.46) | CSF1R | |
| SCHEMBL12884207 | 0.84 | PTGER1 (0.36) | CSF1RLMNA | |
| SCHEMBL12884195 | 0.83 | PTGER1 (0.37) | CSF1RLMNA | |
| SCHEMBL8284704 | 0.82 | LMNA (0.40) | CSF1RTLR8LMNA | |
| SCHEMBL12884184 | 0.82 | HTT (0.43) | LMNA | |
| SCHEMBL2534604 | 0.78 | TLR8 (0.36) | TLR8LMNA | |
| SCHEMBL8249720 | 0.78 | PLK1 (0.36) | LMNA | |
| SCHEMBL8283857 | 0.78 | CSF1R (0.57) | CSF1R | |
| SCHEMBL8249756 | 0.78 | LMNA (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | MAVS, EIF2AK2, SARS1 | CSF1R 1347/4885TLR8 729/4885TLR7 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.